Moreover, hepatic-specific deletion of Glut9 resulted in decreased serum ALT and AST levels (Fig. 5B), decreased TG content in the serum and liver (Fig. S5A) and improved steatosis and fibrosis (Figs. 5C and S5, B–D). This evidence concerns the gene GPT and steatosis.